Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact-Reference-Cited by-同舟云学术

Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact

Published:2023-04-12 Issue:3 Volume:199 Page:445-456
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Garcia-Tejedor Amparo^ORCID,Falo Catalina,Fernandez-Gonzalez Sergi,Laplana Maria,Gil-Gil Miguel,Soler-Monso Teresa,Martinez-Perez Evelyn,Calvo Iris,Calpelo Hugo,Bajen Maria-Teresa,Benitez Ana,Ortega Raul,Petit Anna,Guma Anna,Campos Miriam,Stradella Agostina,Lopez-Ojeda Ana,Ponce Jordi,Pla Maria J.,Pernas Sonia^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-023-06926-y.pdf

Reference32 articles.

1. Burstein HJ (2020) Systemic therapy for estrogen receptor-positive, her2-negative breast cancer. N Engl J Med 383(26):2557–2570

2. Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA: J Am Med Assoc Am Med Assoc 321:288–300

3. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A et al (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11(24):8715–8721

4. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685

5. Sella T, Weiss A, Mittendorf EA, King TA, Pilewskie M, Giuliano AE et al (2021) Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol 7(11):1700–1708